BioLineRx Ltd. (BLRX) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 7 Buy.
Analysts estimate Earnings Per Share (EPS) of $-0.80 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.12 vs est $-0.80 (beat +85%). 2025: actual $-0.29 vs est $-0.09 (missed -214.7%). Analyst accuracy: 0%.
BLRX Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to BioLineRx Ltd. in the past 3 months
EPS Estimates — BLRX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.12
vs Est –$0.80
▲ 566.5% off
2025
Actual –$0.29
vs Est –$0.09
▼ 68.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — BLRX
28%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.029B
vs Est $0.007B
▲ 76.7% off
2025
Actual $0.001B
vs Est $0.000B
▲ 66.8% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
